Correction: Review of the novel antifungal drug olorofim (F901318) Authors: Yuri Vanbiervliet, Tine Van Nieuwenhuyse, Robina Aerts, Katrien Lagrou, Isabel Spriet, Johan Maertens Published: 2024 Correction: BMC Infect Dis 24, 1256 (2024) https://doi.org/10.1186/s12879-024–10143-3 Following publication of the original article [1], the authors identified an error in Table 2 specifically in the AUC-values and Cmax values, which were mistakenly mixed up between two studies during the final compilation of the data. While this does not change the overall conclusions of the paper, the authors believe it is important to correct the record to maintain the integrity of the research. Originally published Table 2: Table 2Pharmacological properties of olorofim. PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration)Pharmacological properties of olorofimParameterMain findingsStudied speciesStudy informationOral bioavailability45–82%, administration irrespective of food administrationRats, Mice, Cynomolgus MonkeysHealthy Male and Female VolunteerSingle oral and IV dosing (mg/kg)Open-label study with fed and fasted conditionsCmax2.2 µg/mLHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAUC0−inf11.9 µg.h/mL(1.31–40.94 µg.h/mL)Healthy male volunteersSingle IV administration 4 mg/kg over 4 hT1/224–30 hHealthy male volunteersSingle IV administration 4 mg/kg over 4 hPlasma protein binding99.7%Rats, Mice, Cynomolgus MonkeysSingle oral and IV dosing ( mg/kg)Vd2.89–3.49 L/kg + CNS distributionHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAdministration via nasogastric tubeSimilar systemic exposure, Cmax 91.44%, AUC 87.62% compared to oralHealthy male and Female VolunteersOpen-label study comparing administration methodsEnterohepatic recirculationSecondary peaks observed, suggesting enterohepatic recirculationHealthy male volunteersMulti-dose IV and oral dosing studiesBlood–brain barrier crossingPotential for CNS penetration(mean brain ratio of 1:1)RatsSingle 2-h IV infusion of 14C-olorofim (10 mg/kg)Dosing- PO: 150 mg BID on day 1, then 90 mg BID- IV: no standard doseMetabolism and eliminationHepatic metabolismDrug-drug interactionsWeak CYP3A4 inhibitor, CYP3A4 substratePK/PD TargetCmin/MICAdverse events- PO: mild gastrointestinal intolerance- IV: infusion reactions Table 2Pharmacological properties of olorofim. PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration)Pharmacological properties of olorofimParameterMain findingsStudied speciesStudy informationOral bioavailability45–82%, administration irrespective of food administrationRats, Mice, Cynomolgus MonkeysHealthy Male and Female VolunteerSingle oral and IV dosing (mg/kg)Open-label study with fed and fasted conditionsCmax2.2 µg/mLHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAUC0−inf11.9 µg.h/mL(1.31–40.94 µg.h/mL)Healthy male volunteersSingle IV administration 4 mg/kg over 4 hT1/224–30 hHealthy male volunteersSingle IV administration 4 mg/kg over 4 hPlasma protein binding99.7%Rats, Mice, Cynomolgus MonkeysSingle oral and IV dosing ( mg/kg)Vd2.89–3.49 L/kg + CNS distributionHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAdministration via nasogastric tubeSimilar systemic exposure, Cmax 91.44%, AUC 87.62% compared to oralHealthy male and Female VolunteersOpen-label study comparing administration methodsEnterohepatic recirculationSecondary peaks observed, suggesting enterohepatic recirculationHealthy male volunteersMulti-dose IV and oral dosing studiesBlood–brain barrier crossingPotential for CNS penetration(mean brain ratio of 1:1)RatsSingle 2-h IV infusion of 14C-olorofim (10 mg/kg)Dosing- PO: 150 mg BID on day 1, then 90 mg BID- IV: no standard doseMetabolism and eliminationHepatic metabolismDrug-drug interactionsWeak CYP3A4 inhibitor, CYP3A4 substratePK/PD TargetCmin/MICAdverse events- PO: mild gastrointestinal intolerance- IV: infusion reactions Pharmacological properties of olorofim. PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration) Rats, Mice, Cynomolgus Monkeys Healthy Male and Female Volunteer Single oral and IV dosing (mg/kg) Open-label study with fed and fasted conditions 11.9 µg.h/mL (1.31–40.94 µg.h/mL) Potential for CNS penetration (mean brain ratio of 1:1) - PO: 150 mg BID on day 1, then 90 mg BID - IV: no standard dose - PO: mild gastrointestinal intolerance - IV: infusion reactions Corrected Table 2: Table 2Pharmacological properties of olorofim.PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration)Pharmacological properties of olorofimParameterMain findingsStudied speciesStudy informationOral bioavailability45%−82%, administration irrespective of food administrationRats, Mice, Cynomolgus MonkeysHealthy Male and Female VolunteerSingle oral and IV dosing (mg/kg)Open-label study with fed and fasted conditionsCmax3.26 µg/mlHealthy male volunteersSingle IV administration 4 mg/kg over 4 h2.21 µg/ml(1.50–3.23 µg/ml)Healthy volunteersMulti-dose oral1.66 µg/ml(0.53–3.75 µg/ml)Patients with IFDMulti-dose oralAUC0-inf40.94 µg.h/mLHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAUC0–24 h23.8 µg.h/ml(16.6–31.4 µg.h/ml)Healthy volunteersMulti-dose oralAUC0–24 h20.7 µg.h/ml(7.59–52.5 µg.h/ml)Patients with IFDMulti-dose oralT1/224–30 hHealthy male volunteersSingle IV administration 4 mg/kg over 4 hPlasma protein binding99.7%Rats, Mice, Cynomolgus MonkeysSingle oral and IV dosing ( mg/kg)Vd2.89–3.49L/kg + CNS distributionHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAdministration via nasogastric tubeSimilar systemic exposure, Cmax 91.44%, AUC 87.62% compared to oralHealthy male and Female VolunteersOpen-label study comparing administration methodsEnterohepatic recirculationSecondary peaks observed, suggesting enterohepatic recirculationHealthy male volunteersMulti-dose IV and oral dosing studiesBlood–brain barrier crossingPotential for CNS penetration(mean brain ratio of 1:1)RatsSingle 2-h IV infusion of 14C-olorofim (10 mg/kg)Dosing- PO: 150 mg BID on day 1, then 90 mg BID- IV: no standard doseMetabolism and eliminationHepatic metabolismDrug-drug interactionsWeak CYP3A4 inhibitor, CYP3A4 substratePK/PD TargetCmin/MICAdverse events- PO: mild gastrointestinal intolerance- IV: infusion reactions Table 2Pharmacological properties of olorofim.PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration)Pharmacological properties of olorofimParameterMain findingsStudied speciesStudy informationOral bioavailability45%−82%, administration irrespective of food administrationRats, Mice, Cynomolgus MonkeysHealthy Male and Female VolunteerSingle oral and IV dosing (mg/kg)Open-label study with fed and fasted conditionsCmax3.26 µg/mlHealthy male volunteersSingle IV administration 4 mg/kg over 4 h2.21 µg/ml(1.50–3.23 µg/ml)Healthy volunteersMulti-dose oral1.66 µg/ml(0.53–3.75 µg/ml)Patients with IFDMulti-dose oralAUC0-inf40.94 µg.h/mLHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAUC0–24 h23.8 µg.h/ml(16.6–31.4 µg.h/ml)Healthy volunteersMulti-dose oralAUC0–24 h20.7 µg.h/ml(7.59–52.5 µg.h/ml)Patients with IFDMulti-dose oralT1/224–30 hHealthy male volunteersSingle IV administration 4 mg/kg over 4 hPlasma protein binding99.7%Rats, Mice, Cynomolgus MonkeysSingle oral and IV dosing ( mg/kg)Vd2.89–3.49L/kg + CNS distributionHealthy male volunteersSingle IV administration 4 mg/kg over 4 hAdministration via nasogastric tubeSimilar systemic exposure, Cmax 91.44%, AUC 87.62% compared to oralHealthy male and Female VolunteersOpen-label study comparing administration methodsEnterohepatic recirculationSecondary peaks observed, suggesting enterohepatic recirculationHealthy male volunteersMulti-dose IV and oral dosing studiesBlood–brain barrier crossingPotential for CNS penetration(mean brain ratio of 1:1)RatsSingle 2-h IV infusion of 14C-olorofim (10 mg/kg)Dosing- PO: 150 mg BID on day 1, then 90 mg BID- IV: no standard doseMetabolism and eliminationHepatic metabolismDrug-drug interactionsWeak CYP3A4 inhibitor, CYP3A4 substratePK/PD TargetCmin/MICAdverse events- PO: mild gastrointestinal intolerance- IV: infusion reactions Pharmacological properties of olorofim.PO (oral), IV (intravenous), CNS (central nervous system), MIC (minimal inhibitory concentration), Cmin (trough concentration) Rats, Mice, Cynomolgus Monkeys Healthy Male and Female Volunteer Single oral and IV dosing (mg/kg) Open-label study with fed and fasted conditions 2.21 µg/ml (1.50–3.23 µg/ml) 1.66 µg/ml (0.53–3.75 µg/ml) 23.8 µg.h/ml (16.6–31.4 µg.h/ml) 20.7 µg.h/ml (7.59–52.5 µg.h/ml) Potential for CNS penetration (mean brain ratio of 1:1) - PO: 150 mg BID on day 1, then 90 mg BID - IV: no standard dose - PO: mild gastrointestinal intolerance - IV: infusion reactions The text referring to Table 2 (page 8, row 222) was also modified accordingly (added text in bold): “Table 2 provides an overview of the pharmacological properties of olorofim based on PK studies across various animal models and in healthy human volunteers and patients with IFD.” The original article has been corrected.